Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $6.60, $0.81 better than the analyst estimate of $5.79. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.06 billion.

GUIDANCE:

Jazz Pharmaceuticals sees FY2025 EPS of $22.50-$24.00, versus the consensus of $22.03.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.